Sorcero Raises $42.5M Series B to Scale AI Platform for Life Sciences Evidence Generation
核心洞察
Sorcero (搜索) secured $42.5 million in Series B financing led by NewSpring Capital (搜索) to expand its AI-powered intelligence platform across medical affairs, safety, and scientific communications segments globally.
The platform serves one-third of the top 30 global pharmaceutical companies, delivering 18x faster insights and improving scientific evidence generation productivity by up to 92%.
Sorcero (搜索)'s medically-tuned AI processes over 263 million publications and 1.3 billion citations globally, achieving 96.1% clinical inclusion accuracy that surpasses FDA regulatory thresholds.
Sorcero (搜索), an AI-powered intelligence platform for life sciences, announced $42.5 million in Series B financing led by NewSpring Growth, with participation from Leawood Venture Capital (搜索) and Blu Ventures (搜索). The funding brings the company's total capital raised to $59 million and will accelerate expansion across medical affairs, safety, scientific communications, and medical device segments globally.
The Washington, DC-based company serves one-third of the top 30 global pharmaceutical companies, helping them discover actionable insights from medical data and drive evidence-based engagement with healthcare professionals. Companies using Sorcero (搜索) report improving productivity in generating scientific evidence by up to 92%, accelerating insight generation by up to 72%, and delivering published evidence, manuscripts, and value dossiers two to five months faster than manual efforts.
Addressing Critical Industry Challenges
The life sciences industry faces significant adoption challenges despite substantial R&D investments. Precision medicine (搜索) and specialty drugs (搜索) now represent over 80% of new approved products, yet new complex medicines take years to secure broad adoption and coverage. With over 1,300 drugs in Phase III development and 76% of new products securing less than 50% payor coverage in six months, the quality and speed-to-market of scientific publishing and evidence have become critical factors.
Healthcare professional engagement presents additional obstacles. An estimated 70% of healthcare professionals believe that pharmaceutical representatives don't understand their needs, while 62% are overwhelmed by the volume of irrelevant promotional content. According to the company, inadequate understanding of patient and customer needs is one of the leading causes why drug launches underperform.
AI-Powered Medical Intelligence Platform
The Sorcero (搜索) Intelligence Platform includes four key components: Sorcero Medical™, Sorcero SciComms™, Sorcero Safety™, and Sorcero Medtech™. The platform combines Agentic AI specifically trained for life sciences, the industry's largest medically-enriched data pool, and architecture designed for regulatory and privacy needs of life sciences.
Sorcero (搜索) unifies fragmented global data and real-world evidence into actionable, compliant intelligence. The platform integrates hundreds of sources to create a 360-degree view of over 40 million healthcare professionals and 100 million published scientists worldwide. Medically-tuned AI agents ingest, analyze, and validate information to ensure 96.1% clinical inclusion accuracy, surpassing the 95% FDA regulatory threshold and PhD-level human performance.
Unlike traditional medical outreach informed primarily by U.S.-only claims data and prescription volumes, Sorcero (搜索) reads more than 263 million publications and 1.3 billion citations globally, including every congress session, report, survey, CRM interaction, safety case, and medical inquiry. This approach identifies which key opinion leaders and doctors are active in specific research areas or treating relevant patient populations.
Strategic Vision and Market Position
"Our vision is to create a unified intelligence platform for the precision medicine (搜索) era," said Dipanwita Das, CEO and co-founder at Sorcero (搜索). "We're pioneering a new evidence-based medical affairs model where science, personalized for physicians, drives engagement and product adoption. This puts doctors' evidence needs at the center and helps life sciences generate real-world insights radically faster, identify patients in need of specific treatments, and continually improve patient outcomes to drive healthcare provider adoption."
The platform continuously monitors product efficacy and safety, providing the precise, real-time insights precision medicine (搜索) practitioners expect, and allowing life sciences customers to engage healthcare professionals with the right information at the right time.
Investor Confidence and Strategic Partnerships
"We see tremendous potential in AI helping pharma engage the right doctors with the right evidence at the right time and ultimately serve patients who can't wait months for critical information on life-changing therapies," said Hart Callahan, NewSpring General Partner. "Sorcero (搜索) is uniquely positioned to become the vertical AI platform precision medicine (搜索) demands and provide the medical insights that get treatments to patients faster."
Dan Goldsmith, life sciences software veteran and investor, emphasized the company's competitive advantages: "We invested in Sorcero (搜索) because their time-to-replicate advantage and expanding data network create a widening moat as they scale. As specialty therapeutics become the norm, life sciences organizations must be data-driven and science-focused to improve therapy adoption."
Sorcero (搜索) maintains strategic partnerships with Google Cloud (搜索), Springer Nature (搜索), ServiceNow (搜索), USDM Life Sciences (搜索), and Snowflake, with built-in GxP, GVP, GDPR, and SOC II compliance and pharmacovigilance capabilities. The company's recent acquisition of Axiom Health (搜索) accelerates its expansion into the medical device market.
Founded in 2018, Sorcero (搜索) is a Certified B Corp that has received recognition as Google's Partner of the Year for Healthcare & Life Sciences, inclusion in Fortune's America's Most Innovative Companies, and the Inc. 5000 fastest-growing private companies list, along with seven foundational medical AI patents.